SEC Comment Letter 0000000000-26-004483 to Vor Biopharma Inc. (VOR)
Vor Biopharma Inc.
Date: May 1, 2026 · CIK: 0001817229 · Accession: 0000000000-26-004483
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295346
Letter
May 1, 2026 Jean-Paul Kress Chief Executive Officer Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed April 27, 2026 File No. 333-295346 Dear Jean-Paul Kress: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Madison Jones, Esq.
Show Raw Text
May 1, 2026 Jean-Paul Kress Chief Executive Officer Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed April 27, 2026 File No. 333-295346 Dear Jean-Paul Kress: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Madison Jones, Esq.